A medtech headhunter’s perspective on talent, innovation, and an industry caught in the crossfire of geopolitics.
In medtech, we spend a lot of time talking about innovation. Breakthrough devices. Clinical need. Better patient outcomes.
But there’s a conversation happening more quietly in the background—one that’s becoming harder to ignore. Politics is starting to interfere with which technologies actually make it to market.
As a medtech headhunter, I sit in a unique position. Every day, I speak with founders, investors, clinicians, and commercial leaders across global markets. And increasingly, I hear the same message:
“Our product works. It’s approved. Physicians want it. But we can’t close deals because of where we’re from.”
This isn’t about weak science or poor data. It’s about perception. It’s about geopolitics. And it’s about risk—real or perceived—shaping decisions that used to be based purely on clinical value.
It’s also becoming more common.
There was a time when regulatory approval was the main hurdle. Achieve CE Mark or FDA clearance, demonstrate strong outcomes, and the path to adoption was relatively clear.
That’s no longer the case.
Today, I’m seeing companies with compelling clinical evidence and clear patient benefit still struggle to convert opportunities into revenue. Procurement teams are more cautious. Distributors are more selective. Hospital systems are increasingly risk-averse.
And when geopolitical considerations enter the discussion, priorities shift. Decisions move away from “Does this help patients?” toward “Does this introduce risk?”
The result is predictable. Deals stall. Partnerships pause. Market entry plans slow down or stop entirely. Not because the technology doesn’t work, but because the company’s origin raises questions that no one feels comfortable answering.
This challenge doesn’t stop at commercialisation. It’s starting to affect talent as well.
At the senior level, people are thoughtful about where they place their careers. I’m seeing top executives hesitate before joining certain companies—not because of the opportunity, but because of perceived geopolitical exposure.
Investors are asking tougher questions. Candidates are looking for stability. Boards are becoming more cautious.
All of this makes it harder for high-potential businesses to build the teams they need to scale, and in medtech, execution is everything.
I’ve seen this play out firsthand. Over the past few years, I’ve worked with companies developing genuinely breakthrough technologies across cardiovascular, neurovascular, and surgical markets. The science is strong. The products are differentiated. The teams are committed.
And yet, I’ve watched hiring processes stall, offers get pulled, and expansion plans quietly shelved.
Not because of product-market fit. Not because of capability.
Because of the political climate surrounding where the company is based.
It’s frustrating from a business perspective. But more importantly, it has real consequences.
Behind every delayed deal is a patient waiting for a better solution.
Of course, national security, regulation, and ethical considerations matter. They should. But when broad assumptions begin to replace informed, evidence-based decisions, the industry creates a different kind of risk—the risk of slowing down innovation that could improve or save lives.
Medtech has always been a global industry. Innovation crosses borders. Talent moves internationally. Clinical need is universal.
Patients don’t care where a device comes from. They care that it works.
What’s needed now is a more balanced approach—one that acknowledges risk without allowing it to overshadow clinical reality. Decisions should be grounded in data, not driven solely by perception. Innovation should be judged on its impact, not its origin.
From where I sit, too many companies are being evaluated on the wrong criteria, and the consequences extend far beyond commercial performance.
As a headhunter, my role is to build the teams that bring innovation to life. But it also gives me a front-row seat to the pressures shaping this industry.
Right now, those pressures are shifting in a way that deserves more attention.
Because when politics closes doors, patients don’t just face delays. They lose access. They miss out on better outcomes. Sometimes, they never get the option at all.
This industry exists to improve and save lives. That should remain the standard we measure everything against.
Patients should come first. Decisions should be grounded in science. Innovation deserves a fair path to market. And talent—like technology—should be able to move where it’s needed most.
Anything less, and we risk holding back the very progress this industry was built to deliver.
